Poxel
Develops drugs for metabolic diseases, including NASH, rare diseases, and an approved diabetes drug.
POXEL | PA
Overview
Corporate Details
- ISIN(s):
- FR0012432516
- LEI:
- 9695003OIX0T7NX72N26
- Country:
- France
- Address:
- 259 AVENUE JEAN JAURES, 69007 LYON
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Poxel SA is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for metabolic diseases. The company's pipeline includes two mid-stage candidates: PXL065 for non-alcoholic steatohepatitis (NASH) and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator for rare diseases. Poxel also developed TWYMEEG® (Imeglimin), a treatment for type 2 diabetes that is approved and marketed in Japan by its partner, Sumitomo Pharma, from which Poxel receives royalties and sales-based payments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-24 07:30 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 287.9 KB | ||
| 2025-11-24 07:30 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 266.9 KB | ||
| 2025-11-13 18:47 |
Quarterly Report
Quarterly financial reporting / Third quarter financial report
|
English | 201.5 KB | ||
| 2025-11-13 18:47 |
Quarterly Report
Information financière trimestrielle / Information financière du troisième trim…
|
French | 178.6 KB | ||
| 2025-11-05 19:28 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 126.0 KB | ||
| 2025-11-05 13:46 |
Report Publication Announcement
Inside Information / Other news releases
|
English | 33.9 KB | ||
| 2025-11-05 13:46 |
Report Publication Announcement
Informations privilégiées / Autres communiqués
|
French | 33.9 KB | ||
| 2025-11-05 11:28 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 192.6 KB | ||
| 2025-10-31 18:52 |
Board/Management Information
Inside Information / Other news releases
|
English | 102.6 KB | ||
| 2025-10-31 18:52 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 153.9 KB | ||
| 2025-10-20 17:45 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 118.9 KB | ||
| 2025-10-20 17:45 |
Regulatory News Service
Inside Information / Other news releases
|
English | 104.6 KB | ||
| 2025-10-16 17:51 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 225.2 KB | ||
| 2025-10-16 17:51 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 253.0 KB | ||
| 2025-08-08 17:45 |
Delisting Announcement
Inside Information / Other news releases
|
English | 109.8 KB |
Automate Your Workflow. Get a real-time feed of all Poxel filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Poxel
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Poxel via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-29 | N/A | Other | Buy | 80,000 | N/A |
Peer Companies
